Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from VYNE Therapeutics ( (VYNE) ).
On December 12, 2025, VYNE Therapeutics Inc. held its annual meeting of stockholders where three proposals were considered. The election of two Class I directors was approved, with Elisabeth Sandoval Little and Steven Basta elected to serve until the 2028 annual meeting. The selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Additionally, stockholders approved the compensation for the company’s named executive officers.
The most recent analyst rating on (VYNE) stock is a Hold with a $0.36 price target. To see the full list of analyst forecasts on VYNE Therapeutics stock, see the VYNE Stock Forecast page.
Spark’s Take on VYNE Stock
According to Spark, TipRanks’ AI Analyst, VYNE is a Neutral.
VYNE Therapeutics faces substantial financial and operational challenges, with persistent unprofitability and cash flow issues being the most significant concerns. The recent Nasdaq non-compliance notice further exacerbates the risk profile, overshadowing any short-term technical stability. The negative valuation metrics highlight the company’s struggle to deliver shareholder value.
To see Spark’s full report on VYNE stock, click here.
More about VYNE Therapeutics
VYNE Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing innovative therapies for dermatological conditions. The company is committed to addressing unmet needs in dermatology through its product offerings.
Average Trading Volume: 1,955,892
Technical Sentiment Signal: Sell
Current Market Cap: $13.45M
For detailed information about VYNE stock, go to TipRanks’ Stock Analysis page.